Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case-Control Study.
Maria AlbaneseGiulia MarroneAgostino PaolinoManuela Di LauroFrancesca Di DanieleCarlo ChiaramonteCartesio D'AgostiniAnnalisa RomaniAlessandro CavaliereCristina GuerrieroAndrea MagriniNicola Biagio MercuriNicola Di DanieleAnnalisa NocePublished in: Pharmaceuticals (Basel, Switzerland) (2022)
Ultramicronized palmitoylethanolamide (um-PEA), a compound with antioxidant, anti-inflammatory and neuroprotective properties, appears to be a potential adjuvant treatment for early stages of Coronavirus disease 2019 (COVID-19). In our study, we enrolled 90 patients with confirmed diagnosis of COVID-19 that were randomized into two groups, homogeneous for age, gender and BMI. The first group received oral supplementation based on um-PEA at a dose of 1800 mg/day for a total of 28 days; the second group was the control group (R.S. 73.20). At baseline (T0) and after 28 days of um-PEA treatment (T1), we monitored: routine laboratory parameters, inflammatory and oxidative stress (OS) biomarkers, lymphocytes subpopulation and COVID-19 serological response. At T1, the um-PEA-treated group presented a significant reduction in inflammation compared to the control group (CRP p = 0.007; IL-6 p = 0.0001; neutrophils to lymphocytes ratio p = 0.044). At T1, the controls showed a significant increase in OS compared to the treated group (FORT p = 0.05). At T1, the um-PEA group exhibited a significant decrease in D-dimer levels ( p = 0.0001) and higher levels of IgG against SARS-CoV-2 ( p = 0.0001) compared to the controls. Our data demonstrated, in a randomized clinical trial, the beneficial effects of um-PEA in both asymptomatic and mild-symptomatic patients related to reductions in inflammatory state, OS and coagulative cascade alterations.
Keyphrases
- coronavirus disease
- sars cov
- oxidative stress
- respiratory syndrome coronavirus
- anti inflammatory
- end stage renal disease
- newly diagnosed
- peripheral blood
- chronic kidney disease
- mental health
- randomized controlled trial
- body mass index
- dna damage
- peritoneal dialysis
- prognostic factors
- double blind
- risk assessment
- artificial intelligence
- blood brain barrier
- placebo controlled
- phase iii
- weight gain
- patient reported outcomes
- heat shock
- combination therapy
- drug induced
- patient reported